US Bancorp DE Acquires 4,843 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

US Bancorp DE boosted its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 40.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,919 shares of the company’s stock after acquiring an additional 4,843 shares during the period. US Bancorp DE’s holdings in iTeos Therapeutics were worth $130,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ITOS. GSA Capital Partners LLP purchased a new stake in iTeos Therapeutics during the third quarter valued at approximately $263,000. Empowered Funds LLC lifted its position in iTeos Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 65,767 shares of the company’s stock valued at $671,000 after acquiring an additional 3,350 shares during the last quarter. Quest Partners LLC lifted its position in iTeos Therapeutics by 914.7% during the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock valued at $113,000 after acquiring an additional 9,934 shares during the last quarter. Intech Investment Management LLC purchased a new stake in iTeos Therapeutics during the third quarter valued at approximately $154,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in iTeos Therapeutics during the third quarter valued at approximately $242,000. Hedge funds and other institutional investors own 97.16% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on ITOS shares. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 6th. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a report on Wednesday, March 5th. JPMorgan Chase & Co. decreased their price target on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, March 6th. Finally, Wells Fargo & Company reduced their target price on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, March 6th.

iTeos Therapeutics Stock Performance

ITOS stock opened at $7.32 on Monday. The firm has a market cap of $279.58 million, a PE ratio of -2.32 and a beta of 1.38. The firm’s fifty day moving average is $7.47 and its 200 day moving average is $9.00. iTeos Therapeutics, Inc. has a one year low of $6.67 and a one year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.13. Research analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.